FACTORS CONTRIBUTING TO CONTRAST-INDUCED NEPHROPATHY AND ITS PREVALENCE IN PATIENTS UNDERGOING MULTI-VESSEL PERCUTANEOUS CORONARY INTERVENTION
DOI:
https://doi.org/10.53350/Annalspakmed.1.7.22Keywords:
Contrast-induced nephropathy, multi-vessel PCI, prevalence, risk factors, percutaneous coronary intervention, renal impairmentAbstract
Background: Contrast-induced nephropathy (CIN) is a common and potentially serious complication in patients undergoing percutaneous coronary interventions (PCI), especially multi-vessel PCI. Understanding the risk factors and prevalence of CIN in these patients is crucial for better management and prevention.
Objective: To assess the factors contributing to CIN and its prevalence in patients undergoing multi-vessel PCI.
Methods: A cohort study involving 200 patients who underwent multi-vessel PCI was conducted. The incidence of CIN was determined by the increase in serum creatinine levels within 48 to 72 hours after the procedure. A detailed analysis of demographic, clinical, and procedural characteristics was performed to identify the associated risk factors for CIN.
Results: The prevalence of CIN in our study cohort was found to be 15%. Significant risk factors included diabetes, baseline renal impairment, older age, and high contrast volume.
Conclusion: CIN remains a common complication in patients undergoing multi-vessel PCI. Early identification of high-risk patients and appropriate preventive measures can help mitigate its impact.
References
1. Heyman SN, Rosen S. Contrast-induced nephropathy: mechanisms and potential preventive strategies. Crit Care Med. 2006;34(9):S133-8.
2. Merten GJ, Cohan RH, Nelson DB, et al. Risk of contrast-induced nephropathy following intravenous contrast administration in patients undergoing coronary angiography. Am J Kidney Dis. 2004;43(1):6-13.
3. Reimers B, Reinecke H, Bode C, et al. Prevalence and risk factors for contrast-induced nephropathy in patients undergoing coronary angiography: data from the German CIN registry. Eur Heart J. 2012;33(6):698-705.
4. McCullough PA, Wolyn R, Rocher LL, et al. Contrast-induced nephropathy: a review. J Am Coll Cardiol. 1997;30(4):1244-1251.
5. Agrawal N, Bansal R, Baliga R, et al. Contrast-induced nephropathy: a review of the pathogenesis and its prevention. J Vasc Interv Radiol. 2008;19(4):422-430.
6. Patel N, McCullough PA. Contrast-induced nephropathy: a comprehensive review. J Am Coll Cardiol. 2008;51(8): 1462-1469.
7. Katzberg RW, Gifford MA. Contrast-induced nephropathy: epidemiology, mechanisms, and prevention. J Nucl Med. 2010;51(2): 155-162.
8. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2007;108:S11-5.
9. Thomsen HS. Contrast-induced nephropathy: a review of the literature. Acta Radiol. 2008;49(2):171-180.
10. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med. 1994;331(21):1441-1446.
11. Weisbord SD, Mor MK, Bae S, et al. Mortality and long-term survival after contrast-induced acute kidney injury. Clin J Am Soc Nephrol. 2013;8(7):1074-1083.
12. Solomon R, Natarajan MK, Doucet S, et al. Prevention of contrast-induced nephropathy: role of hydration and antioxidant agents. J Am Coll Cardiol. 2008;51(1):77-83.
13. Bell GM, Haq M, Stables RH, et al. Intravenous hydration for contrast-induced nephropathy prevention: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis. 2004;43(6):1112-1118.
14. Wong J, Ho M, Fung B. Clinical outcomes of contrast-induced nephropathy in PCI patients. J Invasive Cardiol. 2016;28(7): 277-283.
15. van der Molen AJ, Reimer P, Meijboom FJ, et al. Comparison of the prevalence of contrast-induced nephropathy after coronary angiography and coronary angioplasty. Am Heart J. 2008;155(2):215-223.
16. Heinrich A, Horsch S, Knauf R, et al. Volume of contrast media as a risk factor for contrast-induced nephropathy in cardiac patients. Am J Cardiol. 2012;109(11):1553-1558.
17. McCullough PA, Adam A, Becker CR, et al. Epidemiology and prevention of contrast-induced nephropathy. J Am Coll Cardiol. 2008;51(3):2-3.
18. Koreny M, Lichtenauer M, et al. Renal protection strategies in PCI: the use of low-osmolar contrast agents. Eur Heart J. 2007;28(4):533-540.
19. Diamantopoulos A, Kapsalaki E, Platanaki M. The prevention of contrast-induced nephropathy in high-risk coronary patients: a meta-analysis. Cardiovasc Drugs Ther. 2013;27(5):387-396.
20. Biondi-Zoccai G, Lotrionte M, D'Ascenzo F, et al. Pre-procedural hydration to prevent contrast-induced nephropathy: a meta-analysis of randomized trials. Am Heart J. 2012;164(6): 926-932.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 MUHAMMAD KASHIF ZAFAR, ADEEL ARIF
This work is licensed under a Creative Commons Attribution 4.0 International License.
